Grail's Stock Recovery Potential Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Fool
- Revenue Growth: Grail's revenue surged from $93 million in 2022 to $147 million in 2025, with analysts projecting a 25% CAGR to $287 million by 2028, indicating strong demand among affluent customers and select employers.
- FDA Approval Prospects: Despite lacking FDA approval for its Galleri blood test, Grail sold over 56,000 tests on a cash-only basis in Q1 2026, demonstrating robust market demand, and its integration with Epic's Aura network is expected to further boost sales.
- NHS Trial Results Analysis: Although Grail's NHS England trial did not meet its primary endpoint, users of Galleri showed lower rates of late-stage cancer detection, particularly Stage IV, highlighting the test's potential in early cancer detection.
- Significant Market Opportunity: Should the FDA grant premarket approval for Galleri within the next 12 months, Grail's enterprise value could easily double, with analysts estimating its total addressable market could expand to $100 billion, potentially yielding substantial returns and making it an attractive acquisition target.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 68.950
Low
38.00
Averages
60.86
High
83.71
Current: 68.950
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL and its executives for securities fraud related to the NHS-Galleri cancer trial, resulting in a significant stock drop of 50.55% on February 20, 2026.
- Stock Price Plunge: Following the announcement of the NHS-Galleri trial's top-line results on February 19, 2026, GRAIL's stock fell from $101.53 to $50.21, a loss of $51.32 per share, as the trial failed to meet its primary endpoint despite some favorable results.
- Legal Basis: The lawsuit is based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors having until August 4, 2026, to apply to lead the case, indicating a severe impact on investor trust regarding the company's disclosures.
- Company Impact: As a company focused on early cancer detection, GRAIL's inability to demonstrate the effectiveness of its NHS-Galleri trial may affect its future financing and market credibility, thereby influencing its business strategy and market positioning.
See More
GRAIL Faces Class Action After Trial Failure
- Severe Market Reaction: GRAIL, Inc. lost over $2.2 billion in market capitalization following the announcement of its NHS-Galleri trial results, with shares plummeting more than 50% the next day, reflecting extreme investor disappointment and a collapse of confidence in the company's future prospects.
- Legal Action Initiated: Investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, and suffered significant losses have filed a securities class action lawsuit, alleging that the company and its executives violated federal securities laws and seeking compensation for their losses.
- Trial Design Controversy: The lawsuit focuses on GRAIL's disclosures regarding the NHS-Galleri trial design, accusing the company of misleading investors by creating the false impression that it would significantly reduce late-stage cancer diagnoses, leading to erroneous expectations about the company's future performance.
- Ongoing Investigation: Hagens Berman is investigating when GRAIL's management became aware of the need for a longer follow-up period and encourages individuals with knowledge to come forward to assist in the investigation of potential misconduct by the company.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc., targeting investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging the company concealed critical information regarding the NHS Galleri trial, resulting in investor losses.
- Allegation Details: The complaint claims that GRAIL failed to demonstrate a significant reduction in Stage III-IV cancers in the NHS Galleri trial and did not provide detailed trial results, potentially hiding trends that indicated a longer timeline was necessary to achieve the primary endpoint, impacting investor decisions.
- Stock Price Impact: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, leading to a significant drop in the company's stock price, reflecting market disappointment with the trial results.
- Investor Action: Investors must apply by August 4, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out for more information.
See More
Investors Alert: Class Action Lawsuits Against Badger Meter and Others
- Lawsuit Overview: A shareholder class action lawsuit against Badger Meter, Inc. alleges that the company made materially false or misleading statements from April 18, 2024, to April 16, 2026, regarding customer orders and demand, potentially leading to investor losses.
- Legal Consultation Info: Affected investors are encouraged to contact Holzer & Holzer law firm for legal advice at 888-508-6832 or visit their website for more information, indicating the firm's commitment to supporting victims.
- Grail, Inc. Lawsuit: The class action lawsuit against Grail, Inc. alleges that the company failed to disclose material facts related to its NHS-Galleri trial between May 13, 2025, and February 19, 2026, impacting investor decisions.
- PicS N.V. Lawsuit: The shareholder class action against PicS N.V. claims that misleading statements were made in the offering documents during its January 2026 IPO regarding credit evaluation procedures, potentially causing investor losses.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is accused of distorting its financial results from 2024 to 2026 by prematurely recognizing customer orders, which concealed weakening demand and could adversely affect future revenue performance, impacting investor confidence.
- PicS Lawsuit: PicS N.V. faces allegations of failing to disclose deficiencies in its credit evaluation procedures in its offering documents, leading to a reclassification of approximately R$590 million in exposures and an additional R$88 million expected credit loss, potentially undermining investor trust in the company's financial health.
- Verra Mobility Lawsuit: Verra Mobility Corporation is accused of not disclosing the critical nature of its contract renewal with Avis for its growth plans in Commercial Services, which could severely impact its 2026 performance expectations and influence investor decisions.
- Grail Lawsuit: Grail, Inc. is alleged to have misrepresented management's confidence in trial results, potentially misleading investors regarding the achievability of primary endpoints, which could affect the company's future market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled the market regarding its NHS-Galleri trial's effectiveness in reducing Stage III-IV cancers, concealing adverse facts while presenting an overly optimistic view of the trial's prospects.
- Market Reaction Impact: As the market learned the truth about GRAIL, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL and its executives for securities fraud related to the NHS-Galleri cancer trial, resulting in a significant stock drop of 50.55% on February 20, 2026.
- Stock Price Plunge: Following the announcement of the NHS-Galleri trial's top-line results on February 19, 2026, GRAIL's stock fell from $101.53 to $50.21, a loss of $51.32 per share, as the trial failed to meet its primary endpoint despite some favorable results.
- Legal Basis: The lawsuit is based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors having until August 4, 2026, to apply to lead the case, indicating a severe impact on investor trust regarding the company's disclosures.
- Company Impact: As a company focused on early cancer detection, GRAIL's inability to demonstrate the effectiveness of its NHS-Galleri trial may affect its future financing and market credibility, thereby influencing its business strategy and market positioning.
See More
GRAIL Faces Class Action After Trial Failure
- Severe Market Reaction: GRAIL, Inc. lost over $2.2 billion in market capitalization following the announcement of its NHS-Galleri trial results, with shares plummeting more than 50% the next day, reflecting extreme investor disappointment and a collapse of confidence in the company's future prospects.
- Legal Action Initiated: Investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, and suffered significant losses have filed a securities class action lawsuit, alleging that the company and its executives violated federal securities laws and seeking compensation for their losses.
- Trial Design Controversy: The lawsuit focuses on GRAIL's disclosures regarding the NHS-Galleri trial design, accusing the company of misleading investors by creating the false impression that it would significantly reduce late-stage cancer diagnoses, leading to erroneous expectations about the company's future performance.
- Ongoing Investigation: Hagens Berman is investigating when GRAIL's management became aware of the need for a longer follow-up period and encourages individuals with knowledge to come forward to assist in the investigation of potential misconduct by the company.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc., targeting investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging the company concealed critical information regarding the NHS Galleri trial, resulting in investor losses.
- Allegation Details: The complaint claims that GRAIL failed to demonstrate a significant reduction in Stage III-IV cancers in the NHS Galleri trial and did not provide detailed trial results, potentially hiding trends that indicated a longer timeline was necessary to achieve the primary endpoint, impacting investor decisions.
- Stock Price Impact: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, leading to a significant drop in the company's stock price, reflecting market disappointment with the trial results.
- Investor Action: Investors must apply by August 4, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out for more information.
See More
Investors Alert: Class Action Lawsuits Against Badger Meter and Others
- Lawsuit Overview: A shareholder class action lawsuit against Badger Meter, Inc. alleges that the company made materially false or misleading statements from April 18, 2024, to April 16, 2026, regarding customer orders and demand, potentially leading to investor losses.
- Legal Consultation Info: Affected investors are encouraged to contact Holzer & Holzer law firm for legal advice at 888-508-6832 or visit their website for more information, indicating the firm's commitment to supporting victims.
- Grail, Inc. Lawsuit: The class action lawsuit against Grail, Inc. alleges that the company failed to disclose material facts related to its NHS-Galleri trial between May 13, 2025, and February 19, 2026, impacting investor decisions.
- PicS N.V. Lawsuit: The shareholder class action against PicS N.V. claims that misleading statements were made in the offering documents during its January 2026 IPO regarding credit evaluation procedures, potentially causing investor losses.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is accused of distorting its financial results from 2024 to 2026 by prematurely recognizing customer orders, which concealed weakening demand and could adversely affect future revenue performance, impacting investor confidence.
- PicS Lawsuit: PicS N.V. faces allegations of failing to disclose deficiencies in its credit evaluation procedures in its offering documents, leading to a reclassification of approximately R$590 million in exposures and an additional R$88 million expected credit loss, potentially undermining investor trust in the company's financial health.
- Verra Mobility Lawsuit: Verra Mobility Corporation is accused of not disclosing the critical nature of its contract renewal with Avis for its growth plans in Commercial Services, which could severely impact its 2026 performance expectations and influence investor decisions.
- Grail Lawsuit: Grail, Inc. is alleged to have misrepresented management's confidence in trial results, potentially misleading investors regarding the achievability of primary endpoints, which could affect the company's future market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit Over Misleading Statements
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled the market regarding its NHS-Galleri trial's effectiveness in reducing Stage III-IV cancers, concealing adverse facts while presenting an overly optimistic view of the trial's prospects.
- Market Reaction Impact: As the market learned the truth about GRAIL, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, demonstrating the firm's commitment to protecting investor rights.
See More
